Covered recipient · General Payments record
DANIEL F SOTERES
Allopathic & Osteopathic Physicians Allergy & Immunology Allergy
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2024 · Entire year
$122,810.91
242 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2024 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $75,831.28 | 25 |
| Consulting Fee | $33,573.08 | 11 |
| Travel and Lodging | $7,373.48 | 33 |
| Food and Beverage | $6,033.07 | 173 |
By paying entity
PY2024 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| GENZYME CORPORATION | $29,690.78 | 35 |
| BioCryst US Sales Co., LLC | $22,644.11 | 28 |
| CSL Behring | $21,098.66 | 42 |
| AstraZeneca Pharmaceuticals LP | $21,089.79 | 48 |
| Pharming Healthcare, Inc. | $14,934.58 | 13 |
| Takeda Pharmaceuticals U.S.A., Inc. | $12,480.57 | 45 |
| BioMarin Pharmaceutical Inc. | $229.28 | 1 |
| Genentech USA, Inc. | $193.17 | 8 |
| Amgen Inc. | $114.46 | 6 |
| Regeneron Healthcare Solutions, Inc. | $89.47 | 4 |
| Grifols USA, LLC | $69.66 | 3 |
| Novartis Pharmaceuticals Corporation | $61.14 | 3 |
| QOL Medical, LLC | $47.60 | 3 |
| Blueprint Medicines Corporation | $25.22 | 1 |
| Optinose US, Inc. | $21.57 | 1 |
| GlaxoSmithKline, LLC. | $20.85 | 1 |
Page 2 of 5; records 51–100 of 242 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
DANIEL F SOTERES
NPI 1679573588 · CMS profile ID 212108
Allopathic & Osteopathic Physicians / Allergy & Immunology / Allergy
COLORADO SPRINGS, CO
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 2 of 5; records 51–100 of 242 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1679573588?year=2024&recipient=provider&page=2#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- DANIEL F SOTERES, NPI 1679573588, CMS profile ID 212108. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 5; records 51–100 of 242 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1679573588?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
- APA 7
- IndustryPayments. (2026). DANIEL F SOTERES, NPI 1679573588, CMS profile ID 212108. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 5; records 51–100 of 242 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1679573588?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
- Bluebook
- DANIEL F SOTERES, NPI 1679573588, CMS profile ID 212108, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 5; records 51–100 of 242 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1679573588?year=2024&recipient=provider&page=2#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2024
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30
242 matching records · $122,810.91 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 51–100 of 242.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $16.58 | 10/29/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1104274579 | CMS |
| BioCryst US Sales Co., LLC | $11.82 | 10/26/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1117474144 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $41.91 | 10/24/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1137680035 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $15.86 | 10/24/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1137680037 | CMS |
| CSL Behring | $88.90 | 10/23/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1134608425 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $133.73 | 10/23/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1137680021 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $57.58 | 10/23/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1137680023 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $49.35 | 10/23/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1137680025 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $74.34 | 10/23/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1137680027 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $32.05 | 10/23/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1137680029 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $22.51 | 10/23/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1137680031 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $74.21 | 10/23/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1137680033 | CMS |
| Amgen Inc. | $14.69 | 10/22/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1111713826 | CMS |
| AstraZeneca Pharmaceuticals LP | $16.03 | 10/21/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1104467022 | CMS |
| GENZYME CORPORATION | $12.06 | 10/21/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1139683089 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $28.97 | 10/18/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1137680019 | CMS |
| BioCryst US Sales Co., LLC | $109.70 | 10/17/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1117471082 | CMS |
| BioCryst US Sales Co., LLC | $24.07 | 10/17/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1117475500 | CMS |
| CSL Behring | $4,000.00 | 10/17/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1134608423 | CMS |
| AstraZeneca Pharmaceuticals LP | $950.00 | 10/16/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1105536212 | CMS |
| AstraZeneca Pharmaceuticals LP | $15.72 | 10/09/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1104384233 | CMS |
| AstraZeneca Pharmaceuticals LP | $27.89 | 10/08/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1105629670 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $13.60 | 10/08/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1137680015 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $1.99 | 10/08/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1137680017 | CMS |
| Pharming Healthcare, Inc. | $1,800.00 | 10/04/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1132166784 | CMS |
| BioCryst US Sales Co., LLC | $123.24 | 10/02/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1117469353 | CMS |
| BioCryst US Sales Co., LLC | $226.85 | 10/02/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1117475106 | CMS |
| BioCryst US Sales Co., LLC | $6,555.00 | 10/02/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1117476736 | CMS |
| BioCryst US Sales Co., LLC | $128.12 | 10/02/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1117477972 | CMS |
| BioCryst US Sales Co., LLC | $351.96 | 10/02/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1117478788 | CMS |
| BioCryst US Sales Co., LLC | $624.75 | 10/02/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1117479156 | CMS |
| BioCryst US Sales Co., LLC | $1,380.00 | 10/01/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1117480336 | CMS |
| CSL Behring | $27.50 | 09/28/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1134608411 | CMS |
| CSL Behring | $38.56 | 09/28/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1134608413 | CMS |
| CSL Behring | $61.91 | 09/28/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1134608415 | CMS |
| CSL Behring | $695.96 | 09/28/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1134608417 | CMS |
| CSL Behring | $450.00 | 09/28/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1134608419 | CMS |
| CSL Behring | $118.56 | 09/28/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1134608421 | CMS |
| CSL Behring | $135.50 | 09/27/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1134608409 | CMS |
| AstraZeneca Pharmaceuticals LP | $950.00 | 09/26/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1104241447 | CMS |
| GENZYME CORPORATION | $19.79 | 09/26/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1139683083 | CMS |
| Genentech USA, Inc. | $9.53 | 09/26/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1132994563 | CMS |
| AstraZeneca Pharmaceuticals LP | $20.14 | 09/25/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1104781886 | CMS |
| AstraZeneca Pharmaceuticals LP | $31.26 | 09/24/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1104707013 | CMS |
| Regeneron Healthcare Solutions, Inc. | $21.80 | 09/23/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1114187464 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $23.33 | 09/23/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1137680013 | CMS |
| AstraZeneca Pharmaceuticals LP | $20.00 | 09/17/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1105498488 | CMS |
| AstraZeneca Pharmaceuticals LP | $26.48 | 09/09/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1104567732 | CMS |
| Regeneron Healthcare Solutions, Inc. | $22.58 | 08/30/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1114187457 | CMS |
| GENZYME CORPORATION | $7.90 | 08/29/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1139683075 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $693,814.55 | 70 |
| PY2024 | Principal investigator | $899,112.72 | 58 |
| PY2023 | Principal investigator | $685,808.60 | 98 |
| PY2022 | Principal investigator | $515,302.70 | 98 |
| PY2021 | Recipient | $29.95 | 1 |
| PY2021 | Principal investigator | $739,491.48 | 163 |
| PY2020 | Principal investigator | $358,959.54 | 108 |
| PY2019 | Principal investigator | $478,254.04 | 76 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
70 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $25,750.00 | 12/17/2025 | Non-covered Recipient Entity ASTHMA AND ALLERGY ASSOCIATES, PC | A US Phase 3b, Multi-center, Randomized, Double-blind, Double-Dummy Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-Antihista | No dispute reported | 06/30/2026 | 1190309254 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $7,526.55 | 11/25/2025 | Non-covered Recipient Entity ASTHMA AND ALLERGY ASSOCIATES, PC | a phase two a,randomized,double blind,placebo controlled study to assess efficacy and safety of atuliflapon given orally once daily for twelve weeks in adults with moderate to severe uncontrolled asthma | No dispute reported | 06/30/2026 | 1185541116 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $3,260.00 | 11/19/2025 | Non-covered Recipient Entity ASTHMA & ALLERGY ASSOCIATES PC | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET | No dispute reported | 06/30/2026 | 1223288447 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $707.00 | 11/19/2025 | Non-covered Recipient Entity ASTHMA & ALLERGY ASSOCIATES PC | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET | No dispute reported | 06/30/2026 | 1223288449 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $135.48 | 11/15/2025 | Non-covered Recipient Entity ASTHMA AND ALLERGY ASSOCIATES, PC | A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study of Remibrutinib (LOU064) to Investigate the Efficacy, Safety and Tolerability for 52 Weeks in Adult Chronic Spontaneous Urticaria (CSU) Patients Inadequately Controlled by H1-antihi | No dispute reported | 06/30/2026 | 1190306075 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $12,212.17 | 11/10/2025 | Non-covered Recipient Entity ASTHMA AND ALLERGY ASSOCIATES, PC | A Multicenter, Double-blind, Placebo-controlled, Randomized Withdrawal and Open-label Extension Study Followed by Long-term Open-label Treatment Cycles to Assess the Efficacy, Safety and Tolerability of Remibrutinib (LOU064) in Adult Chronic Spontaneous U | No dispute reported | 06/30/2026 | 1190306077 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,044.00 | 10/15/2025 | Non-covered Recipient Entity ASTHMA & ALLERGY ASSOCIATES PC | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET | No dispute reported | 06/30/2026 | 1223286779 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,044.00 | 10/15/2025 | Non-covered Recipient Entity ASTHMA & ALLERGY ASSOCIATES PC | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET | No dispute reported | 06/30/2026 | 1223286781 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $536.00 | 10/15/2025 | Non-covered Recipient Entity ASTHMA & ALLERGY ASSOCIATES PC | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET | No dispute reported | 06/30/2026 | 1223286783 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $707.00 | 10/15/2025 | Non-covered Recipient Entity ASTHMA & ALLERGY ASSOCIATES PC | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET | No dispute reported | 06/30/2026 | 1223286785 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $536.00 | 10/15/2025 | Non-covered Recipient Entity ASTHMA & ALLERGY ASSOCIATES PC | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET | No dispute reported | 06/30/2026 | 1223286787 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,015.00 | 10/15/2025 | Non-covered Recipient Entity ASTHMA & ALLERGY ASSOCIATES PC | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET | No dispute reported | 06/30/2026 | 1223286789 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $23,855.00 | 09/23/2025 | Non-covered Recipient Entity ASTHMA ALLERGY ASSOCIATES PC | A US Phase 3b, Multi-center, Randomized, Double-blind, Double-Dummy Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-Antihista | No dispute reported | 06/30/2026 | 1190307145 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $3,260.00 | 09/17/2025 | Non-covered Recipient Entity ASTHMA & ALLERGY ASSOCIATES PC | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET | No dispute reported | 06/30/2026 | 1223285466 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $707.00 | 09/17/2025 | Non-covered Recipient Entity ASTHMA & ALLERGY ASSOCIATES PC | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET | No dispute reported | 06/30/2026 | 1223285468 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $3,260.00 | 09/17/2025 | Non-covered Recipient Entity ASTHMA & ALLERGY ASSOCIATES PC | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET | No dispute reported | 06/30/2026 | 1223285470 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,015.00 | 09/17/2025 | Non-covered Recipient Entity ASTHMA & ALLERGY ASSOCIATES PC | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET | No dispute reported | 06/30/2026 | 1223285472 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,015.00 | 08/11/2025 | Non-covered Recipient Entity ASTHMA & ALLERGY ASSOCIATES PC | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET | No dispute reported | 06/30/2026 | 1223284095 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,015.00 | 08/11/2025 | Non-covered Recipient Entity ASTHMA & ALLERGY ASSOCIATES PC | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET | No dispute reported | 06/30/2026 | 1223284097 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $36,931.96 | 07/31/2025 | Non-covered Recipient Entity ASTHMA AND ALLERGY ASSOCIATES, PC | ALTA - Albuterol budesonide Treatment in Acute airway obstruction his is a multi-center randomized double-blind 2-period cross-over study evaluating efficacy and safety of repeated doses of PT027 albuterol budesonide pressurized metered dose inhaler pMDI compared to PT007 albuterol pMDI in participants with asthma and acute airway obstruction induced by 2 mannitol challenges 7 hours apart | No dispute reported | 06/30/2026 | 1185541112 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $910.28 | 07/21/2025 | Non-covered Recipient Entity ASTHMA AND ALLERGY ASSOCIATES, PC | A 52-week multicenter, randomized, double-blind, placebo-controlled study to assess efficacy and safety of remibrutinib (LOU064) in adult and adolescent participants with IgE-mediated food allergy. | No dispute reported | 06/30/2026 | 1190308344 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,015.00 | 07/16/2025 | Non-covered Recipient Entity ASTHMA & ALLERGY ASSOCIATES PC | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET | No dispute reported | 06/30/2026 | 1223282624 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $6,265.50 | 07/02/2025 | Non-covered Recipient Entity ASTHMA & ALLERGY ASSOCIATES PC | A STUDY OF TAK-062 IN TREATMENT OF ACTIVE CELIAC DISEASE IN PARTICIPANTS ATTEMPTING A GLUTEN-FREE DIET | No dispute reported | 06/30/2026 | 1223282078 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,015.00 | 06/18/2025 | Non-covered Recipient Entity ASTHMA & ALLERGY ASSOCIATES PC | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET | No dispute reported | 06/30/2026 | 1223281462 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,015.00 | 06/18/2025 | Non-covered Recipient Entity ASTHMA & ALLERGY ASSOCIATES PC | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET | No dispute reported | 06/30/2026 | 1223281464 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,174.00 | 06/18/2025 | Non-covered Recipient Entity ASTHMA & ALLERGY ASSOCIATES PC | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET | No dispute reported | 06/30/2026 | 1223281466 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,083.00 | 06/18/2025 | Non-covered Recipient Entity ASTHMA & ALLERGY ASSOCIATES PC | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET | No dispute reported | 06/30/2026 | 1223281468 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $95,887.93 | 06/15/2025 | Non-covered Recipient Entity ASTHMA AND ALLERGY ASSOCIATES, PC | A US Phase 3b, Multi-center, Randomized, Double-blind, Double-Dummy Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-Antihista | No dispute reported | 06/30/2026 | 1190308340 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $2,439.00 | 05/14/2025 | Non-covered Recipient Entity ASTHMA & ALLERGY ASSOCIATES PC | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET | No dispute reported | 06/30/2026 | 1223279410 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $934.00 | 05/14/2025 | Non-covered Recipient Entity ASTHMA & ALLERGY ASSOCIATES PC | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET | No dispute reported | 06/30/2026 | 1223279412 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,015.00 | 05/14/2025 | Non-covered Recipient Entity ASTHMA & ALLERGY ASSOCIATES PC | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET | No dispute reported | 06/30/2026 | 1223279448 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $497.00 | 05/14/2025 | Non-covered Recipient Entity ASTHMA & ALLERGY ASSOCIATES PC | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET | No dispute reported | 06/30/2026 | 1223279450 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,015.00 | 05/14/2025 | Non-covered Recipient Entity ASTHMA & ALLERGY ASSOCIATES PC | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET | No dispute reported | 06/30/2026 | 1223279452 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $3,424.00 | 05/14/2025 | Non-covered Recipient Entity ASTHMA & ALLERGY ASSOCIATES PC | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET | No dispute reported | 06/30/2026 | 1223279454 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $497.00 | 05/14/2025 | Non-covered Recipient Entity ASTHMA & ALLERGY ASSOCIATES PC | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET | No dispute reported | 06/30/2026 | 1223279456 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $497.00 | 05/14/2025 | Non-covered Recipient Entity ASTHMA & ALLERGY ASSOCIATES PC | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET | No dispute reported | 06/30/2026 | 1223279458 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,174.00 | 04/18/2025 | Non-covered Recipient Entity ASTHMA & ALLERGY ASSOCIATES PC | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET | No dispute reported | 06/30/2026 | 1223278330 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,083.00 | 04/18/2025 | Non-covered Recipient Entity ASTHMA & ALLERGY ASSOCIATES PC | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET | No dispute reported | 06/30/2026 | 1223278332 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $3,260.00 | 04/18/2025 | Non-covered Recipient Entity ASTHMA & ALLERGY ASSOCIATES PC | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET | No dispute reported | 06/30/2026 | 1223278334 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,174.00 | 04/18/2025 | Non-covered Recipient Entity ASTHMA & ALLERGY ASSOCIATES PC | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET | No dispute reported | 06/30/2026 | 1223278336 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,083.00 | 04/18/2025 | Non-covered Recipient Entity ASTHMA & ALLERGY ASSOCIATES PC | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET | No dispute reported | 06/30/2026 | 1223278338 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,525.00 | 04/16/2025 | Non-covered Recipient Entity ASTHMA & ALLERGY ASSOCIATES PC | A STUDY OF TAK-062 IN TREATMENT OF ACTIVE CELIAC DISEASE IN PARTICIPANTS ATTEMPTING A GLUTEN-FREE DIET | No dispute reported | 06/30/2026 | 1223278086 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,652.00 | 04/16/2025 | Non-covered Recipient Entity ASTHMA & ALLERGY ASSOCIATES PC | A STUDY OF TAK-062 IN TREATMENT OF ACTIVE CELIAC DISEASE IN PARTICIPANTS ATTEMPTING A GLUTEN-FREE DIET | No dispute reported | 06/30/2026 | 1223278088 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $574.00 | 04/16/2025 | Non-covered Recipient Entity ASTHMA & ALLERGY ASSOCIATES PC | A STUDY OF TAK-062 IN TREATMENT OF ACTIVE CELIAC DISEASE IN PARTICIPANTS ATTEMPTING A GLUTEN-FREE DIET | No dispute reported | 06/30/2026 | 1223278090 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,120.00 | 04/16/2025 | Non-covered Recipient Entity ASTHMA & ALLERGY ASSOCIATES PC | A STUDY OF TAK-062 IN TREATMENT OF ACTIVE CELIAC DISEASE IN PARTICIPANTS ATTEMPTING A GLUTEN-FREE DIET | No dispute reported | 06/30/2026 | 1223278092 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,500.00 | 04/16/2025 | Non-covered Recipient Entity ASTHMA & ALLERGY ASSOCIATES PC | A STUDY OF TAK-062 IN TREATMENT OF ACTIVE CELIAC DISEASE IN PARTICIPANTS ATTEMPTING A GLUTEN-FREE DIET | No dispute reported | 06/30/2026 | 1223278094 |
| Principal investigator 1 | Eli Lilly and Company | $13,365.00 | 04/10/2025 | Non-covered Recipient Entity ASTHMA AND ALLERGY ASSOCIATES, PC | A LONG-TERM STUDY TO ASSESS THE SAFETY AND EFFICACY OF LEBRIKIZUMAB IN PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1187877115 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $2,439.00 | 03/14/2025 | Non-covered Recipient Entity ASTHMA & ALLERGY ASSOCIATES PC | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET | No dispute reported | 06/30/2026 | 1223276369 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $2,439.00 | 03/14/2025 | Non-covered Recipient Entity ASTHMA & ALLERGY ASSOCIATES PC | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET | No dispute reported | 06/30/2026 | 1223276371 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $934.00 | 03/14/2025 | Non-covered Recipient Entity ASTHMA & ALLERGY ASSOCIATES PC | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET | No dispute reported | 06/30/2026 | 1223276373 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $2,439.00 | 03/14/2025 | Non-covered Recipient Entity ASTHMA & ALLERGY ASSOCIATES PC | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET | No dispute reported | 06/30/2026 | 1223276375 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $934.00 | 03/14/2025 | Non-covered Recipient Entity ASTHMA & ALLERGY ASSOCIATES PC | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET | No dispute reported | 06/30/2026 | 1223276377 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $2,439.00 | 03/14/2025 | Non-covered Recipient Entity ASTHMA & ALLERGY ASSOCIATES PC | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET | No dispute reported | 06/30/2026 | 1223276407 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $934.00 | 03/14/2025 | Non-covered Recipient Entity ASTHMA & ALLERGY ASSOCIATES PC | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET | No dispute reported | 06/30/2026 | 1223276409 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $3,424.00 | 03/14/2025 | Non-covered Recipient Entity ASTHMA & ALLERGY ASSOCIATES PC | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET | No dispute reported | 06/30/2026 | 1223276411 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $497.00 | 03/14/2025 | Non-covered Recipient Entity ASTHMA & ALLERGY ASSOCIATES PC | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET | No dispute reported | 06/30/2026 | 1223276413 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $3,260.00 | 03/14/2025 | Non-covered Recipient Entity ASTHMA & ALLERGY ASSOCIATES PC | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET | No dispute reported | 06/30/2026 | 1223276425 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $497.00 | 03/14/2025 | Non-covered Recipient Entity ASTHMA & ALLERGY ASSOCIATES PC | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET | No dispute reported | 06/30/2026 | 1223276427 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $3,424.00 | 03/14/2025 | Non-covered Recipient Entity ASTHMA & ALLERGY ASSOCIATES PC | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET | No dispute reported | 06/30/2026 | 1223276429 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $497.00 | 03/14/2025 | Non-covered Recipient Entity ASTHMA & ALLERGY ASSOCIATES PC | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET | No dispute reported | 06/30/2026 | 1223276431 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $33,847.94 | 02/27/2025 | Non-covered Recipient Entity ASTHMA ALLERGY ASSOCIATES PC | A Multicenter, Double-blind, Placebo-controlled, Randomized Withdrawal and Open-label Extension Study Followed by Long-term Open-label Treatment Cycles to Assess the Efficacy, Safety and Tolerability of Remibrutinib (LOU064) in Adult Chronic Spontaneous U | No dispute reported | 06/30/2026 | 1190307143 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $2,970.00 | 02/26/2025 | Non-covered Recipient Entity ASTHMA AND ALLERGY ASSOCIATES, PC | ALTA - Albuterol budesonide Treatment in Acute airway obstruction his is a multi-center randomized double-blind 2-period cross-over study evaluating efficacy and safety of repeated doses of PT027 albuterol budesonide pressurized metered dose inhaler pMDI compared to PT007 albuterol pMDI in participants with asthma and acute airway obstruction induced by 2 mannitol challenges 7 hours apart | No dispute reported | 06/30/2026 | 1185541118 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $23,874.53 | 02/24/2025 | Non-covered Recipient Entity ASTHMA AND ALLERGY ASSOCIATES, PC | A Multicenter,Single arm,Open label,Post Authorization,Phase 4 Effectiveness and Safety Study of Tezepelumab in Adult and Adolescent Participants with Severe Asthma including Several Under Studied Populations in the United States | No dispute reported | 06/30/2026 | 1185541114 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $45,083.66 | 02/20/2025 | Non-covered Recipient Entity CRN CLINICAL RESEARCH NETWORK | ALTA - Albuterol budesonide Treatment in Acute airway obstruction his is a multi-center randomized double-blind 2-period cross-over study evaluating efficacy and safety of repeated doses of PT027 albuterol budesonide pressurized metered dose inhaler pMDI compared to PT007 albuterol pMDI in participants with asthma and acute airway obstruction induced by 2 mannitol challenges 7 hours apart | No dispute reported | 06/30/2026 | 1185541120 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $193,757.92 | 01/30/2025 | Non-covered Recipient Entity ASTHMA ALLERGY ASSOCIATES PC | A One Month, Investigator and Participant Blinded Study to Investigate the Efficacy and Safety of Remibrutinib (LOU064) at Multiple Dose Levels in Adult Participants With Peanut Allergy | No dispute reported | 06/30/2026 | 1190306285 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $48,958.00 | 01/30/2025 | Non-covered Recipient Entity ASTHMA ALLERGY ASSOCIATES PC | A 52-week multi-center, randomized, double-blind, placebo controlled, basket study with an open-label extension to investigate the efficacy, safety, and tolerability of remibrutinib (LOU064) in Chronic Inducible Urticaria (CINDU) in adults inadequately co | No dispute reported | 06/30/2026 | 1190306287 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $24,648.00 | 01/28/2025 | Non-covered Recipient Entity ASTHMA ALLERGY ASSOCIATES PC | A Three-year, Multi-center, Double-blind, Extension Study to Evaluate the Long-term Safety and Efficacy of Ligelizumab in Patients Who Completed Ligelizumab's Phase III Studies in Food Allergy | No dispute reported | 06/30/2026 | 1190306289 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $1,479.52 | 01/01/2025 | Non-covered Recipient Entity ASTHMA AND ALLERGY ASSOCIATES, PC | A One Month, Investigator and Participant Blinded Study to Investigate the Efficacy and Safety of Remibrutinib (LOU064) at Multiple Dose Levels in Adult Participants With Peanut Allergy | No dispute reported | 06/30/2026 | 1190308342 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $21,479.20 | 01/01/2025 | Non-covered Recipient Entity ASTHMA AND ALLERGY ASSOCIATES, PC | A 52-week multi-center, randomized, double-blind, placebo controlled, basket study with an open-label extension to investigate the efficacy, safety, and tolerability of remibrutinib (LOU064) in Chronic Inducible Urticaria (CINDU) in adults inadequately co | No dispute reported | 06/30/2026 | 1190308346 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $1,832.91 | 01/01/2025 | Non-covered Recipient Entity ASTHMA AND ALLERGY ASSOCIATES, PC | A Three-year, Multi-center, Double-blind, Extension Study to Evaluate the Long-term Safety and Efficacy of Ligelizumab in Patients Who Completed Ligelizumab's Phase III Studies in Food Allergy | No dispute reported | 06/30/2026 | 1190308348 |